NorthWest Biotherapeutics Inc (NWBO)

[Tony888]

No, the trial remains blinded through crossover:

Here for example, though you can find this all over
Quote:
If scans show that your tumour starts to grow again during treatment, you can start having DCVax-L injections regardless of the group you are in. This is called a ‘crossover option’. You may have already been having the vaccine, or you may have been having the dummy drug – neither you nor your doctor will know. If you go into the crossover option, you still won’t know which treatment you’d been having up until then. But you will definitely be having the vaccine from then on.


Arguably the term "crossover" is a poor term when applied to the treatment arm patents, "retreatment" makes more sense as they do restart the dosing schedule.

Regardless, is is still blinded.

Thanks a lot. This is what I was looking for.

So, someone already receiving vaccine will have less vaccine available after progression whereas someone receiving placebo will have more vaccine available to them after progression. So if DCVax works, time to OS event from PFS event will likely be greater for placebo patients crossing over than vaccine patients crossing over. So in order for there to be a significant OS benefit for patients starting out with receiving the vaccine the PFS benefit of this group has to be significant.